Fig. 2: Overexpression of BCL6 alleviates HFD-induced hepatic steatosis. | Cell Death & Disease

Fig. 2: Overexpression of BCL6 alleviates HFD-induced hepatic steatosis.

From: B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36

Fig. 2

A Schedule of BCL6 overexpression. Six-week-old mice were injected with AAV-Control (as a control) or AAV-BCL6 Flag (overexpressing BCL6) via the tail vein. B The protein expression of BCL6 was tested by western blot analysis. C Bodyweight, D liver weight, E LW/BW, and F food intake of the AAV-Control mice and the AAV-BCL6 mice (n = 6/group). G Triglyceride, H NEFA, I total cholesterol in the livers of the AAV-Control mice and the AAV-BCL6 mice fed an HFD for 16 weeks (n = 6/group). J Representative images of H&E and Oil red O staining of liver tissues from the AAV-Control mice and the AAV-BCL6 mice fed an HFD for 16 weeks. Scale bar, 100 μm. K AST and L ALT levels in liver tissues from the AAV-Control mice and the AAV-BCL6 mice fed an HFD for 16 weeks (n = 6/group). M Representative images of immunohistochemistry staining of F4/80 and sirian red staining of liver tissues from two group mice. Scale bar, 100 μm. Hepatic mRNA levels of (N)IL-6 and TNFα, (O) COL1α1and αSMA from two group mice fed an HFD for 16 weeks (n = 6/group). Data represent the mean ± SEM, *P < 0.05, **P < 0.01,***P < 0.001 and N.S. indicates no significance between the two indicated groups.

Back to article page